DDInter1878 DDInter1960
A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.
Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds.[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements.[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.[A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt. To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.
Tripelennamine {u} (Compound) resembles {v} (Compound) Dimetacrine
Tripelennamine {u} (Compound) resembles {v} (Compound) Chloropyramine
Tripelennamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brompheniramine
Tripelennamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Tripelennamine {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Tripelennamine {u} (Compound) binds {v} (Gene) HRH1
Tripelennamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Tripelennamine {u} may lead to a major life threatening interaction when taken with {v} Zonisamide
Tripelennamine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Disopyramide
Tripelennamine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orphenadrine
Tripelennamine (Compound) resembles Dimetacrine (Compound)
Tripelennamine (Compound) resembles Chloropyramine (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Tripelennamine may lead to a major life threatening interaction when taken with Dextropropoxyphene
Tripelennamine (Compound) binds HRH1 (Gene)
Tripelennamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Tripelennamine may lead to a major life threatening interaction when taken with Zonisamide
Tripelennamine (Compound) resembles Disopyramide (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide
Tripelennamine (Compound) resembles Orphenadrine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine